Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...

The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...

Leerink Partners analyst David Risinger has reiterated their bullish stance on VRTX stock, giving a Buy rating yesterday.Invest with ...

In trading on Thursday, shares of Vertex Pharmaceuticals, Inc. (Symbol: VRTX) entered into oversold territory, hitting an RSI reading of 24.8, after changing hands as low as $377.85 per share.

Piper Sandler lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $533 from $535 and keeps an Overweight rating on the shares ...

Shares of Vertex Pharmaceuticals fell more than 10% premarket ... The stock was among the top 10 trending symbols on Stocktwits as retail sentiment for the biotech firm plunged to ‘extremely ...

The startups are the fourth and fifth drugmakers to file for initial stock sales since late December — the most IPO activity ...

Shares of Vertex Pharmaceuticals Inc. VRTX inched 0.72% higher to $408.18 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX ...

Vertex Pharmaceuticals Inc. closed 18.39% short of its 52-week high of $519.88, which the company reached on November 8th.

View Vertex Pharmaceuticals Incorporated (VRTX) current and estimated P/E ratio data provided by Seeking Alpha.

Vertex has built an empire in cystic fibrosis (CF) treatment, recently crowning its dominance with Alyftrek's approval last month. This latest CF drug adds even more firepower to a franchise ...